Top in cardiology: Health effect of 500 extra steps per day; racism and heart disease risk
Click Here to Manage Email Alerts
Every additional 500 steps walked could reduce the risk for a CVD event by about 14% in older adults, according to a presenter at American Heart Association’s Epidemiology, Prevention, Lifestyle & Cardiometabolic Health Scientific Sessions.
“Steps are an easy way to measure physical activity, and more daily steps were associated with a lower risk of having a cardiovascular disease-related event in older adults,” Erin E. Dooley, PhD, an assistant professor of epidemiology at the University of Alabama at Birmingham School of Public Health, said in a press release.
It was the top story in cardiology last week.
Another top story was about an association between coronary heart disease and Black women’s experience with racism in facets like housing, the criminal justice system and employment. Women in the highest quartile of perceived interpersonal racism in daily life had a 21% increased risk for incident coronary heart disease compared with women in the lowest quartile.
Read these and more top stories in cardiology below:
500 extra steps per day could reduce CV risk for adults 70 years and older
For every 500 extra steps per day, or an additional one-quarter mile walked, adults aged 70 years or older could reduce risk for a CVD event by approximately 14%, a speaker reported. Read more.
Interpersonal racism drives heart disease risk for Black women
Perceived experiences of racism in employment, housing and the criminal justice system were associated with increased incidence for coronary heart disease among Black women, researchers reported. Read more.
Anxiety, depression more common among teens, young adults who vape nicotine, marijuana
Teens and young adults who report vaping nicotine, marijuana or both are significantly more likely to experience anxiety and depression compared with never vapers, survey data show. Read more.
FDA issues complete response letter for omecamtiv mecarbil
The FDA has issued a complete response letter to Cytokinetics for omecamtiv mecarbil, an investigational, selective small molecule cardiac myosin activator for treatment of heart failure with reduced ejection fraction, according to a press release. Read more.
Bempedoic acid an ‘effective alternative’ for statin-intolerant patients: CLEAR Outcomes
In the CLEAR Outcomes trial, bempedoic acid reduced risk for major cardiovascular events by 13% compared with placebo, including a 23% lower risk for myocardial infarction, among adults with a history of CVD or at high risk deemed statin intolerant. Read more.